Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Lung Cancer. 2018 May;119:42-47. doi: 10.1016/j.lungcan.2018.02.019. Epub 2018 Mar 2.
Circulating tumor DNA (ctDNA) shed from cancer cells into the peripheral blood can be non-invasively collected and tested for the presence of tumor-specific mutations. Mutations identified in ctDNA can predict responses to targeted therapies and emerging evidence suggests that changes in ctDNA levels over time can be used to monitor response to therapy and detect disease recurrence. Given the emergence of targeted therapies in advanced non-small cell lung cancer (NSCLC), liquid biopsies utilizing ctDNA testing represent a powerful approach to genotype tumors and monitor for the development of resistance. Here, we review current and potential future clinical applications of ctDNA testing for patients with advanced NSCLC.
循环肿瘤 DNA（ctDNA）从癌细胞脱落到外周血中，可以进行非侵入性采集和检测肿瘤特异性突变。ctDNA 中鉴定的突变可以预测对靶向治疗的反应，并且有新的证据表明，ctDNA 水平随时间的变化可以用于监测治疗反应和检测疾病复发。鉴于在晚期非小细胞肺癌（NSCLC）中出现了靶向治疗，利用 ctDNA 检测的液体活检代表了一种对肿瘤进行基因分型和监测耐药性发展的强大方法。在这里，我们回顾了 ctDNA 检测在晚期 NSCLC 患者中的当前和潜在未来临床应用。
